Abstract: The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.

Abstract: The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention N and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

Abstract: Antibodies against mammal secreted Klotho protein The invention relates to new antibodies raised against mammal secret isoform of Klotho protein. There are disclosed antibodies against murine and human Klotho proteins, as well as kits and compositions comprising them. The invention also relates to the use of these antibodies as research tools in biochemical and molecular biology assays.

Abstract: The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.

Abstract: The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.

Abstract: Method for producing adenovirus vectors for gene therapy and auxiliary vectors used therefor. The method is based on the multiplication of gutless adenoviruses that lack adenovirus-coding sequences by cotransfecting them with an auxiliary or helper adenovirus that has an attB sequence of the &phis;C31 bacteriophage inserted between the adenovirus packaging signal and the ITR closest to it and/or utilizing the delay arising at the time of packaging the helper adenovirus with respect to that of the gutless adenovirus owing to the presence of the atttB sequence in order to recover the gutless adenovirus from the culture before the helper adenovirus completes its viral cycle. This gives rise to high gutless adenovirus titres that are essentially free from helper adenovirus, thereby allowing them to be used in gene therapy, minimizing the likelihood of the appearance of a cellular immune response on the part of the treated individual against cells transduced by the adenovirus vector produced.

Abstract: Recombinant Canine Adenovirus (CAV) vectors based on CAV-2 strain Toronto in which the CAV-2 E1 region has been deleted are described herein. Methods for the preparation of recombinant vectors include the use of transcomplementation cell lines which are specifically employed to reduce the likelihood of generating replication competent CAV-2 during propagation of the vectors. The resultant replication-defective, E1-deficient CAV preparations are highly desirable for the transfer of nucleic acid sequences in vitro and in vivo.